PET with radioabeled aminoacids

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 56, Issue 2, 2012, Pages 151-162

  Crippa, F ^a   Alessi, A ^a   Serafini, G L ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Diagnostic imaging; Glioma; Radiation oncology

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; AMINO ACID; FLUOROAZOMYCIN ARABINOSIDE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLTYROSINE F 18; METHIONINE C 11; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

BRAIN TUMOR; CLINICAL ASSESSMENT; CYCLOTRON; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INDICATION; GLIOMA; HUMAN; ISOTOPE LABELING; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE; BRAIN; METHODOLOGY; SCINTISCANNING;

AMINO ACIDS; BRAIN; BRAIN NEOPLASMS; HUMANS; ISOTOPE LABELING; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 84864392035     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. De Chiro G. Positron emission tomography using [18F]fluodeoxyglucose in brain tumor. A powerful diagnostic and prognostic tool. Invest Radiol 198/;22:360-371
2. 18F-FDG PET in oncology. J Nucl Med 2008;49:480-508.
3. Olivero WC, Dulebohn SC, Lister JR. The use of PET in evaluating patients with primary brain tumors: is it useful? J Neurol Neurosurg Psychiatry 1995;58:250-2.
4. Benard F, Romsa J, Hustinx R. Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Sem Nucl Med 2003;33:148-62. (Pubitemid 36577057)
5. 18F]fluoro-d- deoxy-D-glucose in the low-grade glioma. Neurosurgery 1996;39:470-6.
6. Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? Am J Neuroradiol 1998;19:407-13. (Pubitemid 30422740)
7. Langleben DD, Segal GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 2000;41:1861-7.
8. Chao ST, Suh JH, Raja S, Lee SY, Barnett G. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001;96:191-7. (Pubitemid 32520674)
9. Ishiwata K, Kubota K, Murakami M, Kubota R, Sasaki T, Ishii S et al. Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med 1993;34:1936-43. (Pubitemid 23331262)
10. Jager PL, Vaalburg W, Pruinm J, de Vries EG, Langen KJ, Piers DS. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432-45. (Pubitemid 32207394)
11. Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 1990;70:43-77. (Pubitemid 20037281)
12. Palacin M, Estevez R, Bertran J, Zorzano A. Molecular biology of mammalian plasma membrane amino acid transportes. Physiol Rev 1998;78:969-1054. (Pubitemid 28491947)
13. Hyde R, Taylor PM, Hundal HS. Amino acid transporters: roles in amino acid sensing and signalling in animal cells. Biochem J 2003;274:19738-44.
14. Busch H, Davis JR, Honig GR, Anderson DC, Nair PV, Nyhan WL. The uptakes of a variety of amino acids into nuclear proteins of tumor and other tissues. Cancer Res 1959;19:1030-9.
15. Isselbacher KJ. Increased uptake of amino acids and 2-deoxy-2-glucose by virus-transformed cells in culture. Proc Natl Acad Sci USA 1972;69:585-9.
16. Isselbacher KJ. Sugar and amino acid transport by cells in culture: differences between normal and malignant cells. N Engl J Med 1972;286:929-33.
17. Laverman P, Boerman OC, Corstens FH, Oyen WJ. Fluorinated amino acids for tumor imaging with positron emission tomography. Eur J Nucl Med Mol Imaging 2002;29:681-90. (Pubitemid 34439330)
18. Miyagawa T, Oku T, Uehara H, Desai R, Beattie B, Tjuvajev J et al. "Facilitated" amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab 1998;18:500-9. (Pubitemid 28213534)
19. Sasajima T, Miyagawa T, Oku T, Gelovani JG, Finn R, Blasberg R. Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines. Eur J Nucl Med Mol Imaging 2004;31:1244-56:
20. 11C]Methionine and rubidium-82 using PET. J Neurol Sci 1995;132:20-7.
21. 11C-L-Methionine Positron Emission Tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 2008;10:1-18.
22. Kubota R, Kubota K, Yamada S, Tada M, Takahashi T, Iwata R et al. Methione uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med 1995;36:484-92.
23. Ogawa T, Miura S, Murakami M, Iida H, Hatazawa J, Inugami A et al. Quantitative evaluation of neutral amino acid transport in cerebral gliomas using positron emission tomography and fluorine-18 fluorophenylalanine. Eur J Nucl Mol Imaging 1996;23:889-95. (Pubitemid 26278787)
24. Shoup TM, Olson J, Hoffman JM, Votaw J, Eshima D, Eshima L et al. Synthesis and evaluation of [18F]l-amino-3-flrocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med 1999;40:331-8. (Pubitemid 29077098)
25. Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 1999;40:205-12. (Pubitemid 29044193)
26. 11C] Methionine uptale in brain tumors: initial results of a comparative study. Eur J Nucl Med 2000;27:542-9.
27. Langen KJ, Jarosch M, Mühlensiepen H, Hamacher K, Bröer S, Jansen P et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol 2003;30:501-8. (Pubitemid 36776519)
28. 123I-iodo-methyl-L-tyrosine SPECT in brain tumors. J Nucl Med 2004;45:374-81.
29. 18F-fluoethyl)-L-tyrosine PET for diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004;31:1464-70.
30. Mosskin M, Ericson K, Hindmarsh T, von Holst H, Collins VP, Bergström M et al. Positron emission tomography compared twith magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as refrence. Acta Radiol 1989;30:225-32. (Pubitemid 19152548)
31. 11C-methionine in cerebral glioma patients studied with PET. Acta Neurochir (Wien) 1990;104-8-12.
32. Ogawa T, Hatazawa J, Inugami A, Murakami M, Fujita H, Shimosegawa E et al. Carbon 11-methionine PET evaluation of intracerebral hematoma: distinguishing neoplstic from non-neoplastic hematoma. J Nucl Med 1995;36:2175-9.
33. Sasaki M, Kuwabara Y, Yoshida T, Nakagawa M, Fukumura T, Mihara F et al. A comparative study of thallium-201 SPET, carbon-11 methione PET and fluorine-18 fluodeoxyglucose PET foor the differentiation of astrocitic tumors. Eur J Nucl Med 1998;25:1261-9. (Pubitemid 28446052)
34. Massager N, David P, Goldman S, Pirotte B, Wikler D, Salmon I et al. Combined magnetic resonance imaging- and positron emission tomography-guided stereotactic biopsy in brainstem mass lesions: diagnostic yield in a series of 30 patients. J Neurosurg 2000;93:951-7. (Pubitemid 32800604)
35. Braun V, Dempf S, Weller R, Reske SN, Schachenmayr W, Ritcher HP. Cranial neuronavigation with direct integration of (11) C-methionine positron emission tomography (PET) data - results of a pilot study in 32 surgical cases. Acta Neurochir (Wien) 2002;144:777-82. (Pubitemid 34985271)
36. 11C]methione. Eur J Nucl Me Mol Imaging 2003;30:1561-7.
37. Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 2004;10:7163-70. (Pubitemid 39487701)
38. Herholz K, Hölzer T, Bauer B, Schröder R, Voges J, Ernestus RI et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998;50:1316-22. (Pubitemid 28240345)
39. Dethy S, Manto M, Kentos A, Konopnicki D, Pirotte B, Goldman S et al. PET findings in a brain abscess associated with a silent atrial septal defect. Clin Neurol Neurosurg 1995;97:349-53.
40. Dethy S, Goldman S, Blecic S, Luxen A, Levivier M, Hildebrand J. Carbon-11-methionine and fluorine-18-FDG PET study in brain hematoma. J Nucl Med 1994;35:1162-6. (Pubitemid 24204117)
41. Ishii K, Ogawa T, Hatazawa J, Kanno I, Inugami A, Fujita H et al. High L-methyl-[11C]Methionine uptake in brain abscess: a PET study. J Comput Assist Tomogra 1993;17:660-1. (Pubitemid 23206756)
42. Ribom D, Schoenmaekers M, Engler H, Smits A. Evaluation of 11C-methionine PET as a surrogate endpoint after treatment of grade-2 gliomas. J Neurooncol 2005;71:325-32. (Pubitemid 40372965)
43. Chung JK, Kim YK, Kim SK, Lee YJ, Paek S, Yeo JS et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002;29:176-82.
44. Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003;64:227-37. (Pubitemid 37203463)
45. Utriainen M, Metsähonkala L, Salmi TT, Utriainen T, Kalimo H, Pihko H et al. Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography. Cancer 1990;95:1376-86.
46. Kameyama M, Shirane R, Itoh J, Sato K, Katakura R, Yoshimoto T et al. The accumulation of 11C-methione in cerebral glioma patients studied with PET. Acta Neurochir (Wien) 1990;104:8-12. (Pubitemid 20202088)
47. Ceyssesns S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. Am J Neuroradiol 2006;27:1432-7. (Pubitemid 44260122)
48. Nariai T, Tanaka Y, Wakimoto H, Aoyagi M, Tamaki M, Ishiwata K et al. Usefulness of L-[methyl-11C]Methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 2005;103:498-507. (Pubitemid 43186642)
49. Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Langstrom B, Bolander H, Bergstrom M, Smits a. Positron emission tomography (11C]-methionine and survival in patients with low-grade gliomas. Cancer 2001;15:1541-9. (Pubitemid 32947840)
50. De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2001;95:746-50. (Pubitemid 33043345)
51. Kim S, Chung JK, Im SH, Jeong JM, Lee DS, Kim DG et al. 11C-methione PET as a prognostc marker in patients with glioma: comparison with 18F.FDG PET. Eur J Nucl Med Mol Imaging 2005;32:52-9. (Pubitemid 40142778)
52. Paulus W, Peiffer J. Intratumoral histologic heterogeneity of gliomas. Cancer 1989;64:442-7.
53. Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 38:1459-62.
54. Pirotte B, Goldman S, Salzberg S, Wikler D, David P, Vandesteene A et al. Combined positron emission tomography and magnetic resonance imaging for the planning of stereotactic brain biopsies in children: experience in 9 cases. Pediatr Neurosurg 2003;38:146-55. (Pubitemid 36302462)
55. Pirotte B, Goldman S, David P, Wikler D, Damhaut P, Vandesteene A et al. Stereotactic brain biopsy guided by positron emission tomography (PET) with [F-18]fluodeoxyglucose and [C-11] Methionine. Acta Neurochir Suppl 1997;68:133-8.
56. Pirotte B, Goldman S, Massanger N, David P, Wikler D, Vandesteene A et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Neurol Neurosurg Psychiatry 1999;66:648-53.
57. Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 2004;10:7163-0.
58. Pirotte B, Goldman S, Massanger N, David P, Wikler D, Lipszyc M et al. Combined use of 18F-fluodeoxyglucose and 11C-methione in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg 2004;101:476-83. (Pubitemid 39100725)
59. Tovi M. MR imaging in cerebral glioma analysis of tumor tissue components. Acta Radiol Suppl 1993;384:1-24.
60. Hawighorst H, Schreiber W, Knopp MV, Essig M, Engenhart-Cabilic R, Brix G et al. Macroscopic tumor volume of malignant glioma determined by contrast-enhanced magnetic resonance imaging with and without magnetization transfer contrast. Magn Reson Imaging 1996;14:119-26.
61. Watanabe M, Tanka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology 1992;34:463-9.
62. Waldman AD, Jackson A, Price SJ, Clark CA, Booth TC, Auer DP et al. Quantitative imaging biomarkers in neuro-oncology. Nat Rev Clin Oncol 2009;6:445-54.
63. Miwa K, Shinoda J, Yano H, Okumura A, Iwama T, Nakashima T et al. Discrepancy between lesion distributions on Methionine PET and MR imaged in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry 2004;75:1457-62. (Pubitemid 39279817)
64. Tang BN-T, Sadeghi N, Branle F, De Witte O, Wikler D, Goldman S. Semi-quantification of Methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. J Neurooncol 2005;71:161-8. (Pubitemid 40796299)
65. Nariai T, Senda M, Ishii K, Maehara T, Wakabayashi S, Toyama H et al. Three-dimensional imaging of cortical structure, function and glioma for tmour resection. J Nucl Med 1997;38:1563-8. (Pubitemid 27443956)
66. Levivier M, Massager N, Wikler D, Lorenzoni J, Ruiz S, Devriendt D et al. Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. J Nucl Med 2004;45:1146-54. (Pubitemid 47611659)
67. Voges J, Herholz K, Hölzer T, Würker M, Bauer B, Pietrzyk U et al. 11C-methionine and 18F-2-fluodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Stereotact Funct Neurosurg 1997;69:129-35.
68. Grosu AL, Lachner R, Wiedenmann N, Stärk S, Thamm R, Kneschaurek P et al. Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methione-PET data for stereotactic radiotherapy using a LINAC: first clinical experience: Int J Radiat Ocol Biol Phys 2003;56:1450-63. (Pubitemid 36842898)
69. Grosu AL, Weber WA, Riedel E, Jeremic B, Nieder C, Franz M et al. L-(methyl-11C)Methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:64-74. (Pubitemid 41583543)
70. Pirotte B, Goldman S, Dewitte O, Massager N, Wikler D, Lefranc F et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg 2006;104:238-53.
71. Pirotte B, Goldman S, Van Boagert P, et al. Integration of [11C] methionine-positron emission tomography and magnetic resonance imaging for image-guided surgical resection of infiltrative low-grade brain tumors in children. J Neurosurg 2005;57:128-39.
72. Grosu AL, Weber WA. PET for radiation treatment planning of brain tumors. Radiotherapy and Oncology 2010;96:325-7.
73. Lilja A, Lundqvist H, Olsson Y, Spannare B, Gullberg P, Langstrom B. Positron emission tomography and computed tomography in differential diagnosis between recurrent or residual glioma and treatment-induced brain lesions. Acta Radiol 1989;30:121-8. (Pubitemid 19084312)
74. Ogawa T, Kanno I, Shishido F, Inugami A, Higano S, Fujita H et al. Clinical value of PET with 18F.fluorodeoxyglucose and L-methil-11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol 1991;32:197-8.
75. Viader F, Derlon JM, Petit-Taboué MC, Shishido F, Hubert P, Houtteville JP et al. Recurrent oligodendroglioma diagnosed with 11C-1-methionine and PET: a case report. Eur Neurol 1993;33:248-51. (Pubitemid 23099152)
76. Sasaki M, Ichiya Y, Kuwabara Y, Yoshida T, Inoue T, Morioka T et al. Hyperperfusion and hypermetabolism in brain radiation necrosis with epileptic activity. J Nucl Med 1996;37:1174-6. (Pubitemid 26329527)
77. Sonoda Y, Kumabe T, Takahashi T, Shirane R, Yoshimoto T. Clinical usefulness of 11C-MET PET and 201T1 SPECT for differentiation of recurrent glioma from radiation necrosis. Neurol Med Chir (Tokyo) 1998;38:342-7.
78. Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg 2003;98:1056-64. (Pubitemid 36460897)
79. Tsuyuguchi N, Takami T, Sunada I, Iwai Y, Yamanaka K, Tanaka K et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery -in malignant glioma. Ann Nucl Med 2004;18:291-6. (Pubitemid 39100096)
80. Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, interobserver variability and prognostic value. Eur J Nucl Med Mol Imaging 2005;32:39-51. (Pubitemid 40142777)
81. Tang BN, Levivier M, Heureux M, Wikler D, Massager N, Devriendt D et al. 11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas. Eur J Nucl Med Mol Imaging 2006;33:169-78. (Pubitemid 43152884)
82. Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 2000;41:1861-7.
83. Thiel A, Pietrzyk U, Sturm V, Herholz K, Hovels M, Schroder R. Enhanced accuracy in differential diagnosis of radiation necrosis by positron emission tomography-magnetic resonance imaging coregistration: technical case report. Neurosurgery 2000;46:232-4. (Pubitemid 30030287)
84. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80. (Pubitemid 20195640)
85. Gerstener ER, Batchelor TT. Imaging and response criteria in gliomas. Current Opinion in Oncology 2010;22:598-603.
86. van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol 2009;27:2905-8.
87. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical feature, mechanism, and management of pseudo-progression in malignant gliomas. Lancer Oncol 2008;9:453-61 (Pubitemid 351597795)
88. Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent M. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 2010;9:906.
89. Pöpperl G, Götz C, Rachinger W, Schnell O, Gildehaus FJ, Tonn JC et al. Serial O-(2[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol imaging 2006;33:792-80.
90. Ullrich RT, Kracht L, Brunn A, Herholz K, Frommolt P, Miletic H et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med 2009;50:1962-8.
91. Mehrkens JH, Pöpperl G, Rachinger W, Herms J, Seelos K, Tatsch K et al. The positive predictive value of O-(2[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol 2008;88:27-35.
92. Rachinger W, Goetz C, Pöpperl G, Gildehaus FJ, Kreth FW, Holtmannspötter M et al. Positron emission tomography with O-(2[18F]fluoroethyl)-L-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurg 2005;57:505-11. (Pubitemid 41254459)
93. Herholz K, Kracht LW, Heiss WD. Monitoring the effect of chemotherapy in a mixed glioma by C-11 methionine PET. J Neuroimaging 2003;13:269-71. (Pubitemid 36775950)
94. Galldiks N, Kracht LW, Burghaus L, Thomas A, Jacobs AH, Heiss WD et al. The use of 11C-methionine PET to monitor the effect of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging 2006;33:516-24.
95. Wyss M, Hofer S, Bruehlmeier M, Hefti M, Uhlmann C, Bartschi E et al. Early metabolic responses in temozolomide treated low-grade glioma patients. J Neurooncol 2009;95:87-93.
96. 11C]methione-positron emission tomography as a biological monitoring toll in the treatment of gliomas. J Neurosurg 2005;103:498-507.
97. Judenhofer MS, Wehrl HF, Newport DF, Catana C, Siegel SB, Becker M et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nature Medicine 2008;14:459-65. (Pubitemid 351499385)
98. Borbely K, Wintermark M, Martos J, Fedorcsak I, Bognar L, Kasler M. The pre-requisite of a second-generation glioma PET biomarker. J Neurol Sciences 2010;298:11-6.